ACOR News and Press, Acorda Therapeutics Inc. From 11/04/19

Camber Energy (NYSEMKT: CEI ) +53% . More news on: Camber Energy, Inc., Wright Medical Group N.V., Enlivex Therapeutics Ltd., Stocks on the move, Read more ...

Acorda Therapeutics (NASDAQ: ACOR ) is scheduled to announce Q3 earnings results on Monday, November 4th, after market close. The consensus EPS Estimate is -$0.51  vs. $0.17 in 3Q18 and the consensus Revenue Estimate is $44.38M (-68.9% Y/Y). Over the last 2 years, acor has be...

AAN , ACOR , ADUS , AOSL , APLE , APTS , AWR , BHF , BKD , BKH , BWXT , CBT , CC , CDE , CDEV , CHGG , CPE , DIOD , DK , DOOR , ED , ETH , EVBG , EVER , FICO , FN , FRPT , FRTA , FTSI , GRPN , HHC , HIG , HLIO , HPR , HR , HTZ , IFF , ITRI , JKHY , KA...

Gainers:  Rexahn Pharmaceuticals (NASDAQ: REXN ) +45% . California Resources Corporation (NYSE: CRC ) +40% . BeiGene (NASDAQ: BGNE ) +34% . El Pollo Loco Holdings (NASDAQ: LOCO ) +28% . Acorda Therapeutics (NASDAQ: ACOR ) +26% . American Axle & Manufacturing Holdings (NYSE: A...

Acorda Therapeutics ( ACOR ) pre-announced Q3 sales of Inbrija and Ampyra along with a restructuring plan. I wrote about the company in July before the company announced Q2 results, and I warned of the difficulties of a new launch and that caution is warranted. The situation has not im...

Gainers:  Lightbridge Corporation (NASDAQ: LTBR ) +19% . Sesen Bio (NASDAQ: SESN ) +17% . Visteon Corporation (NASDAQ: VC ) +17% . Tesla (NASDAQ: TSLA ) +17% . Rigel Pharmaceuticals (NASDAQ: RIGL ) +17% . TrovaGene (NASDAQ: TROV ) +16% . Contango Oil & Gas Company (NYSEMKT: ...

OpGen (NASDAQ: OPGN )  -55%  on  pricing  equity offering. More news on: OpGen, Inc., Nokia Corporation, Twitter, Inc., Stocks on the move, Read more ...

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Market Perform rating and $44 (5% upside) price target at Oppenheimer. More news on: ACADIA Pharmaceuticals Inc., Nektar Therapeutics, Neovasc Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Total non-GAAP operating expenses for the full year 2020 expected to be $180 - $190 million 1 Estimated 2020 operating expenses reduced by ~$60 million compared to 2019 revised guidance - Includes more than $21 million in expected annualized cost savings from headcount reduction ...

“Do Tell” Your Doctor Tool was adapted from a clinically validated questionnaire developed by Duke University, with input from the Parkinson’s community Acorda Therapeutics, Inc. (NASDAQ: ACOR) today announced the launch of the “Do Tell” Your Doctor...